HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 77.1%

Neg 0% Neu 0% Pos 77.1%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $15 to $20.